GSTO and AS3MT genetic polymorphisms and differences in urinary arsenic concentrations among residents in Bangladesh

Biomarkers

Volumn 17, Issue 3, 2012, Pages 240-247

  Rodrigues, Ema G ^a   Kile, Molly ^b   Hoffman, Elaine ^a   Quamruzzaman, Quazi ^c   Rahman, Mahmuder ^c   Mahiuddin, Golam ^c   Hsueh, Yumei ^d   Christiani, David C ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c Dhaka Community Hospital   (Bangladesh)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Arsenic metabolism; Drinking water; Pathway analysis

Indexed keywords

ARSENIC; ARSENIC(III)METHYLTRANSFERASE; CACODYLIC ACID; GLUTATHIONE TRANSFERASE OMEGA; METHANEARSONIC ACID; METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BANGLADESH; CHEMICAL ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME MODIFICATION; FEMALE; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLITE; METAL METABOLISM; RESIDENT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DEFECT; URINE LEVEL; WILD TYPE;

ADULT; ARSENIC; BANGLADESH; FEMALE; GLUTATHIONE TRANSFERASE; HUMANS; MALE; METHYLTRANSFERASES; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84860380361     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2012.658863     Document Type: Article

References (30)

1. Ahsan H, Chen Y, Kibriya MG, Slavkovich V, Parvez F, Jasmine F, Gamble MV, Graziano JH. (2007). Arsenic metabolism, genetic susceptibility, and risk of premalignant skin lesions in Bangladesh. Cancer Epidemiol Biomarkers Prev 16:1270-1278. (Pubitemid 46984970)
2. Breton CV, Zhou W, Kile ML, Houseman EA, Quamruzzaman Q, Rahman M, Mahiuddin G, Christiani DC. (2007). Susceptibility to arsenic-induced skin lesions from polymorphisms in base excision repair genes. Carcinogenesis 28:1520-1525. (Pubitemid 47241801)
3. Challenger F. (1945). Biological methylation. Chemical Reviews 36, 315-361.
4. Chen YC, Guo YL, Su HJ, Hsueh YM, Smith TJ, Ryan LM, Lee MS, Chao SC, Lee JY, Christiani DC. (2003). Arsenic methylation and skin cancer risk in southwestern Taiwan. J Occup Environ Med 45:241-248. (Pubitemid 36347799)
5. Fujihara J, Soejima M, Koda Y, Kunito T, Takeshita H. (2008). Asian specific low mutation frequencies of the M287T polymorphism in the human arsenic (+3 oxidation state) methyltransferase (AS3MT) gene. Mutat Res 654:158-161.
6. Hernández A, Xamena N, Sekaran C, Tokunaga H, Sampayo-Reyes A, Quinteros D, Creus A, Marcos R. (2008a). High arsenic metabolic efficiency in AS3MT287Thr allele carriers. Pharmacogenet Genomics 18:349-355. (Pubitemid 351367528)
7. Hernández A, Xamena N, Surrallés J, Sekaran C, Tokunaga H, Quinteros D, Creus A, Marcos R. (2008b). Role of the Met(287) Thr polymorphism in the AS3MT gene on the metabolic arsenic profile. Mutat Res 637:80-92. (Pubitemid 350256765)
8. Hsueh YM, Hsu MK, Chiou HY, Yang MH, Huang CC, Chen CJ. (2002). Urinary arsenic speciation in subjects with or without restriction from seafood dietary intake. Toxicol Lett 133:83-91.
9. International Agency For Research on Cancer (IARC). (1980). Arsenic and Arsenic Compounds. Lyon: IARC monographs 23.
10. Kile ML, Hoffman E, Hsueh YM, Afroz S, Quamruzzaman Q, Rahman M, Mahiuddin G, Ryan L, Christiani DC. (2009). Variability in biomarkers of arsenic exposure and metabolism in adults over time. Environ Health Perspect 117:455-460.
11. Lindberg AL, Ekström EC, Nermell B, Rahman M, Lönnerdal B, Persson LA, Vahter M. (2008). Gender and age differences in the metabolism of inorganic arsenic in a highly exposed population in Bangladesh. Environ Res 106:110-120. (Pubitemid 350137961)
12. Lindberg AL, Kumar R, Goessler W, Thirumaran R, Gurzau E, Koppova K, Rudnai P, Leonardi G, Fletcher T, Vahter M. (2007). Metabolism of low-dose inorganic arsenic in a central European population: influence of sex and genetic polymorphisms. Environ Health Perspect 115:1081-1086. (Pubitemid 47317076)
13. Loffredo CA, Aposhian HV, Cebrian ME, Yamauchi H, Silbergeld EK. (2003). Variability in human metabolism of arsenic. Environ Res 92:85-91. (Pubitemid 36875703)
14. Marnell LL, Garcia-Vargas GG, Chowdhury UK, Zakharyan RA, Walsh B, Avram MD, Kopplin MJ, Cebrián ME, Silbergeld EK, Aposhian HV. (2003). Polymorphisms in the human monomethylarsonic acid (MMA V) reductase/hGSTO1 gene and changes in urinary arsenic profiles. Chem Res Toxicol 16:1507-1513. (Pubitemid 38049369)
15. McCarty KM, Chen YC, Quamruzzaman Q, Rahman M, Mahiuddin G, Hsueh YM, Su L, Smith T, Ryan L, Christiani DC. (2007). Arsenic methylation, GSTT1, GSTM1, GSTP1 polymorphisms, and skin lesions. Environ Health Perspect 115:341-345. (Pubitemid 46554430)
16. Rodriguez S, Gaunt TR, Day IN. (2009). Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 169:505-514.
17. Schmuck EM, Board PG, Whitbread AK, Tetlow N, Cavanaugh JA, Blackburn AC, Masoumi A. (2005). Characterization of the monomethylarsonate reductase and dehydroascorbate reductase activities of Omega class glutathione transferase variants: implications for arsenic metabolism and the age-at-onset of Alzheimer s and Parkinson s diseases. Pharmacogenet Genomics 15:493-501. (Pubitemid 41017598)
18. Steinmaus C, Yuan Y, Kalman D, Atallah R, Smith AH. (2005). Intraindividual variability in arsenic methylation in a U.S. population. Cancer Epidemiol Biomarkers Prev 14:919-924. (Pubitemid 40478557)
19. Steinmaus C, Yuan Y, Kalman D, Rey OA, Skibola CF, Dauphine D, Basu A, Porter KE, Hubbard A, Bates MN, Smith MT, Smith AH. (2010). Individual differences in arsenic metabolism and lung cancer in a case-control study in Cordoba, Argentina. Toxicol Appl Pharmacol 247:138-145.
20. Styblo M, Del Razo LM, Vega L, Germolec DR, LeCluyse EL, Hamilton GA, Reed W, Wang C, Cullen WR, Thomas DJ. (2000). Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol 74:289-299. (Pubitemid 30660931)
21. Tanaka-Kagawa T, Jinno H, Hasegawa T, Makino Y, Seko Y, Hanioka N, Ando M. (2003). Functional characterization of two variant human GSTO 1-1s (Ala140Asp and Thr217Asn). Biochem Biophys Res Commun 301:516-520. (Pubitemid 36279270)
22. Tseng CH. (2009). A review on environmental factors regulating arsenic methylation in humans. Toxicol Appl Pharmacol 235:338-350.
23. Vahter M. (1999). Methylation of inorganic arsenic in different mammalian species and population groups. Sci Prog 82 (Pt 1):69-88.
24. Vahter M. (2002). Mechanisms of arsenic biotransformation. Toxicology 181-182:211-217.
25. Vega L, Styblo M, Patterson R, Cullen W, Wang C, Germolec D. (2001). Differential effects of trivalent and pentavalent arsenicals on cell proliferation and cytokine secretion in normal human epidermal keratinocytes. Toxicol Appl Pharmacol 172:225-232. (Pubitemid 32406030)
26. Whitbread AK, Tetlow N, Eyre HJ, Sutherland GR, Board PG. (2003). Characterization of the human Omega class glutathione transferase genes and associated polymorphisms. Pharmacogenetics 13:131-144. (Pubitemid 36324243)
27. Wood TC, Salavagionne OE, Mukherjee B, Wang L, Klumpp AF, Thomae BA, Eckloff BW, Schaid DJ, Wieben ED, Weinshilboum RM. (2006). Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies. J Biol Chem 281:7364-7373. (Pubitemid 43847506)
28. Yu RC, Hsu KH, Chen CJ, Froines JR. (2000). Arsenic methylation capacity and skin cancer. Cancer Epidemiol Biomarkers Prev 9: 1259-1262.
29. Zakharyan RA, Aposhian HV. (1999). Enzymatic reduction of arsenic compounds in mammalian systems: the rate-limiting enzyme of rabbit liver arsenic biotransformation is MMA(V) reductase. Chem Res Toxicol 12:1278-1283. (Pubitemid 30013540)
30. Zakharyan RA, Sampayo-Reyes A, Healy SM, Tsaprailis G, Board PG, Liebler DC, Aposhian HV. (2001). Human monomethylarsonic acid (MMA(V)) reductase is a member of the glutathione-S-transferase superfamily. Chem Res Toxicol 14:1051-1057. (Pubitemid 32800161)